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CXCL12 (SDF-1), a CXC-chemokine, and its speciﬁc receptor, CXCR4, have recently been shown to be involved in
tumourgenesis, proliferation and angiogenesis. Therefore, we analysed CXCL12a/CXCR4 expression and function in four
human kidney cancer cell lines (A-498, CAKI-1, CAKI-2, HA-7), 10 freshly harvested human tumour samples and
corresponding normal kidney tissue. While none of the analysed tumour cell lines expressed CXCL12a, A-498 cells were
found to express CXCR4. More importantly, real-time RT–PCR analysis of 10 tumour samples and respective adjacent
normal kidney tissue disclosed a distinct and divergent downregulation of CXCL12a and upregulation of CXCR4 in primary
tumour tissue. To prove that the CXCR4 protein is functionally active, rhCXCL12a was investigated for its ability to induce
changes of intracellular calcium levels in A-498 cells. Moreover, we used cDNA expression arrays to evaluate the biological
inﬂuence of CXCL12a. Comparing gene expression proﬁles in rhCXCL12a stimulated vs unstimulated A-498 kidney cancer
cells revealed speciﬁc regulation of 31 out of 1176 genes tested on a selected human cancer array, with a prominent
stimulation of genes involved in cell-cycle regulation and apoptosis. The genetic changes reported here should provide new
insights into the developmental paths leading to tumour progression and may also aid the design of new approaches to
therapeutic intervention.
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Chemokines constitute a superfamily of small pro-inﬂammatory
cytokines that are involved in a variety of immune reactions
including allergy, inﬂammation, infection, tissue injury, cardiovas-
cular diseases and malignant tissue growth (Wang et al, 1998).
Especially in solid tumours, recent research focused on the subfam-
ily of a- or CXC-chemokines.
The CXCL12 (=SDF-1) gene has been localised to chromosome
10q11.1, which is in contrast to most genes of the other known
CXC chemokines that cluster on chromosomes 4. The ubiquitous
expression of CXCL12 is consistent with the presence of TATA-less
and GC-rich sequences in the 5'-flanking region, as is often found
in so-called ‘housekeeping genes’ (Shirozu et al, 1995). Recent
studies indicate that CXCL12 expression is markedly decreased in
rapidly dividing ﬁbroblasts and liver cells (Jiang et al, 1994),
premalignant colonic adenomas, hepatocellular carcinomas (Shibu-
ta et al, 1997), as well as in various malignant cell lines (Begum et
al, 1996, 1999). Unlike CXCL12, CXCR4 expression has been
shown to be heterogeneous in malignant cells of different origin.
While it was reported to be markedly decreased in hepatocellular
carcinomas (Begum et al, 1999) and increased in glioblastoma
multiforme, breast and uterine cancer as well as Burkitt’s lympho-
ma (Sehgal et al, 1998a; Rempel et al, 2000), it was not found to be
regulated in colon, oesophageal and gastric cancer (Mitra et al,
1999), or in different tumour cell lines (Dwinell et al, 1999;
Murdoch et al, 1999).
In this study we have looked for chemokine receptor expression
in four primary human kidney cancer cell lines, 10 freshly
harvested human tumour samples and the corresponding normal
kidney tissues. Furthermore, we have identiﬁed key molecular
changes induced upon CXCL12/CXCR4 signalling by means of a
cDNA array approach. Genetic changes reported here may provide
new insights into the developmental paths leading to tumour
progression and may also aid the design of new approaches to ther-
apeutic intervention.
MATERIALS AND METHODS
Patients
Written informed consent was obtained from all patients before
entry into the study. Renal cell carcinoma (RCC) and adjacent
normal kidney tissue samples were collected from 10 patients
immediately after tumour nephrectomy. All patients presented with
RCC of the clear cell type and were treated at the Staedtischen
Klinikum Braunschweig between January and June 2001. As patient
6 presented with a large tumour, which macroscopically appeared
to consist of two areas of different cell types, two samples were
taken thereof. Patient 10 suffered from a small tumour that had
not increased in size for more than 12 months before surgery
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acteristics are summarised in Table 1.
Cell lines
Human kidney cancer cell lines A-498, CAKI-1, CAKI-2 and HA-7
(DSMZ Braunschweig, Germany) were grown in RPMI medium
supplemented with 10% heat-inactivated foetal bovine serum
(FBS; Bio Whittaker Europe, Belgium), 2 mM L-glutamine (Gibco
BRL, Scotland, UK), 10 U ml
71 penicillin and 10 mg ml
71 strep-
tomycin (Sigma, Germany); cells were maintained in 95% air/5%
CO2 at 378C.
RT–PCR
Tumour and kidney tissue samples were processed immediately
after surgery. Total RNA was extracted using TriReagent (MRC-
Research, USA), and reverse transcribed with M-MLV reverse tran-
scriptase (Gibco, Scotland, UK) and Oligo dT-primers (Gibco,
Scotland, UK) for 35 min at 428C, according to the manufacturers
instructions. The reaction was stopped by the addition of 40 ml
Tris-EDTA(TE)-buffer (pH=8) and heat-inactivation for 8 min at
908C. The following primers (MWG-Biotech, Ebersberg, Germany)
were used for the subsequent PCR: CXCR1 (sense: 5' CCT TGG
GGG TGG TGG AT 3'; antisense: 5' AGG GCT GCT TGT CTC
GTT C 3'), CXCR2 (sense: 5' TGC CTC ACC CCT TGC CAT
AA 3'; antisense: 5' GCC AGC CTG ATT TTC TTT CTT TTG
3'), CXCR3 (sense: 5' GTG GCC GAG AAA GCA GGG TAG
ACG 3'; antisense: 5' CAG GCG CAA GAG CAG CAT CCA
CAT 3'), CXCR4 (sense: 5' GCC TTA TCC TGC CTG GTA TTG
TC 3'; antisense: 5' GCG AAG AAA GCC AGG ATG AGG AT
3'), CXCR5 (sense: 5' CGG AAA GCA GCT CGA AGG CAC
AGT 3'; antisense: 5' CTC CGT TGG CAA GGG CAG AAG
TAG 3'); CXCL12a (sense: 5' ACT GGG TTT GTG ATT GCC
TCT GAA 3'; antisense: 5' GGA ACC TGA ACC CCT GCT GTG
3'). mRNA integrity and reverse transcription were checked with
primers for the ribosomal protein S 9 (RPS9)-gene (sense: 5'
CGC AGG CGC AGA CGG TGG AAG C 3'; antisense: 5' CGA
AGG GTC TCC GCG GGG TCA CAT 3'), a common ‘housekeep-
ing gene’. PCR was performed with Promega Taq polymerase
(Promega, USA) following the manufacturers instruction. Cycling
conditions: 5 min at 948C, 30 cycles of 30 s at 948C, 30 s at
548C (CXCR1+2) or 588C, 30 s at 728C, and, ﬁnally, 10 min at
728C. PCR products were resolved by electrophoresis on 1.5%
agarose gels and visualised by ethidium bromide staining. Speciﬁ-
city of the ampliﬁed products was established by restriction
enzyme digestion.
Real-time RT–PCR
To quantify CXCR4-, CXCL12a- as well as RPS9-mRNA levels, we
established a real-time RT–PCR assay. For this purpose, we used a
GeneAmp
1 5700 thermal cycler and the Taq-Man
1 Universal
Master Mix (Perkin Elmer) including SYBR
1-Green PCR Core
Reagents, according to the manufacturer’s instructions. Primers
and cycling temperatures were identical with those used for
conventional RT–PCR. All experiments were performed at least
twice. A detailed description can be obtained upon request from
the corresponding author.
Flow cytometry
A-498 cells were removed from ﬂasks non-enzymatically, washed,
and resuspended at 10
6 cells ml
71 in ice cold washing buffer
(phosphate-buffered saline (PBS) containing 0.5% FBS) and incu-
bated with 10 mgm l
71 R-phycoerythrin-labelled mouse anti-
human CXCR4 antibody (12G5; PharMingen, San Diego, USA)
for 90 min at 48C. Cells were analysed with a FACScalibur ﬂow
cytometer (Becton Dickinson, USA).
Calcium mobilisation assay
A-498 cells were grown on 8-chambered glass cover slips (Lab Tek
Brand Products, USA) and loaded with 2 mM fura-2/AM (Molecu-
lar Probes, USA) for 45 min at 378C. Cover slips were transferred
into a FBS-free buffer and fura-2-speciﬁc ﬂuorescence in individual
cells was measured after addition of 2 mgm l
71 rhCXCL12a (R&D
Systems, USA), using a confocal microscope (BIO-Rad, Germany)
with an epiﬂuorescence 640 objective. Emission ﬂuorescence at
510 nm was measured upon excitation at 340 and 380 nm. Data
are presented by the ratio of ﬂuorescence intensity at 340 nm
divided by 380 nm. To establish the integrity of the epithelial cells,
intracellular calcium was also measured using bradykinin (Sigma,
Germany) as control stimulant.
Immunohistochemistry
Formalin-ﬁxed and parafﬁn-embedded archival specimens of clear
cell renal carcinomas with adjacent normal kidney tissue were
deparafﬁnised in xylol following standard methods. For antigen
retrieval, heat pretreatment was performed using a microwave oven
(citrate buffer, pH=6.2; 20 min, 600 W). After blocking endogenous
peroxidase with 3% H2O2 and endogenous biotin by Avidin-Biotin-
Blocking-Kit (Vector Laboratories, CA, USA) the polyclonal goat
anti-human CXCR-4 (fusin, clone A-17; Santa Cruz Biotechnology,
CA, USA) antiserum (1:500) was incubated overnight at 48C. After
washing thoroughly in TRIS buffered saline, a biotinylated second-
ary rabbit-anti-goat-antibody was incubated (1:250, 60 min). The
biotin was detected by an optimised alkaline phosphatase conju-
gated streptavidin-biotin-complex (NEN Life Science, MA, USA).
Fast red served as substrate and haemalaun for counterstaining.
Molecular characterisation of CXCL12a/CXCR4 signalling
A-498 cells were grown in two 75 cm
2 ﬂasks to conﬂuence. Subse-
quently, fresh culture medium was added to both ﬂasks, in one
ﬂask combined with 0.5 mgm l
71 rhCXCL12a. Cells were incu-
bated at 378C for 6 h and 18 h, respectively, and immediately
used for total RNA isolation. Differential expression of 1176 genes
in rhCXCL12a stimulated vs unstimulated A-498 cells was investi-
gated by cDNA array analysis using the Human Cancer 1.2 Array
(Clontech, Germany). Sample preparation was performed as
previously described (Eisen and Brown, 1999). Brieﬂy, total RNA
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Table 1 Patient characteristics and real-time RT–PCR results
Staging and CXCR4 CXCL12a
Patient Sex/Age grading T/N-ratio* T/N-ratio*
1 M/58 T2N0M0, GII 2 0.2
2 M/73 T3bN0M0, GI 43 0.6
3 M/71 T2N0M0, GII 45 0.4
4 F/54 T1N0M0, GII 29 0.2
5 M/65 T2N0M0, GII 28 0.1
6a F/59 T2N0M0, GII 42 0.4
6b F/59 T2N0M0, GII 29 0.8
7 M/63 T1N0M0, GII–III 85 0.3
8 M/55 T1N0M0, GII 28 1.0
9 M/66 T1N0M0, GI 23 0.2
10 M/40 T1N0M0, GII 45 2.3
All patients suffered from conventional (clear cell) renal carcinoma. Patient 6
presented with a large tumour, which macroscopically appeared to consist of two
areas of different cell types; two samples were taken. Patient 10 suffered from a small
tumour which did not increase in size for more than 12 months before surgery and
macroscopically appeared like a benign tumour. TNM-classiﬁcation was used accord-
ing to the International Union Against Cancer (UICC). *Values corrected for RPS9-
expression. M=male; F=female; T=cancer tissue; N=normal kidney tissue.
Chemokine receptor expression in kidney cancer
AJ Schrader et al
1251
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(8), 1250–1256was extracted twice using TriReagent LS and a DNAse I digestion
step in between. 3.5 mg of total RNA from stimulated and unstimu-
lated cultures, respectively, were used as template for the speciﬁc
synthesis of
32P-radiolabelled cDNA probes, according to the
manufacturer’s recommendations (Clontech, Germany), except that
the RT-enzyme was replaced by Superscript II (Gibco, Scotland,
UK). Subsequently, cDNA probes were hybridised side-by-side to
identical gene array membranes (a complete list of cDNAs and
controls immobilised on the Atlas Human Cancer 1.2 Array from
Clontech can be found at http://www.clontech.com). After hybridi-
sation and extensive washes, membranes were exposed to Phosphor
Imaging Screens (Fuji, Japan). Radioactivity was detected using a
Fuji Bas 2500 16-bit image analysis system. Spot density for each
gene was measured using Array-Vision software (Version 5.1,
Imaging Research, Canada), along with numerous quality control
parameters (compare Array-Vision manual). Results were
conﬁrmed in two independent array analyses with consistent
results. To compare density values between both arrays, the expres-
sion level of each gene was normalised to the total of all genes
measured for each sample.
RESULTS
CXCR and CXCL12a mRNA expression
mRNA expression levels of chemokine receptors CXCR1-5 in the
four renal cell cancer cell lines (A-498, CAKI-1, CAKI-2, and
HA-7) were determined by RT–PCR. The only receptor to be
consistently expressed in all, but especially in A-498 tumour cells
was CXCR4 (data not shown).
In order to quantify CXCR4 and CXCL12a expression levels, we
used a real time RT–PCR assay. All four cell lines as well as 10
primary human tumour samples plus adjacent normal kidney
tissues were tested for CXCR4 and CXCL12a as well as for
RPS9-mRNA expression. The latter was used as independent
‘housekeeping-gene’. CXCR4 mRNA was particularly expressed in
A-498 cells; CXCR4/RPS9 expression ratios for A-498, CAKI-1,
CAKI-2, and HA-7 cell lines were 0.98, 0.002, 0.003 and 0.006,
respectively (Figure 1). On the other hand, CXCL12a was hardly
expressed in any cell line (CXCL12a/RPS9 expression ratios ranging
from 0.016–0.005; Figure 1), conﬁrming the results gained by
conventional RT–PCR.
In tumour and corresponding kidney tissue from the 10 patients
with RCC, the distribution of tumour/kidney ratios for CXCR4
and CXCL12a gene expression, calculated by real time RT–PCR
and corrected for that of RPS9 ((CXCR4/RPS9)tumour/(CXCR4/
RPS9)normal kidney and (CXCL12a/RPS9)tumour/(CXCL12a/RPS9)nor-
mal kidney, respectively), is given for each patient in Table 1 and
Figure 1. The median tumour/kidney ratio was 29.6 (range, 2.3–
85.2) for CXCR4, and 0.36 (range, 0.1–2.3) for CXCL12a, respec-
tively, displaying a signiﬁcant upregulation of CXCR4 in malignant
kidney tissue, while its ligand CXCL12a was signiﬁcantly lower
expressed as compared to the corresponding normal renal tissue.
CXCR4 surface expression
CXCR4 cell-surface expression was evaluated by FACS analysis of
all four RCC cell lines using a mouse anti-human CXCR4 and a
matching IgG2a-isotype control antibody. Percentages of FACS-
positive cells and relative mean ﬂuorescence intensities (MFI)
were determined. CAKI-2 and HA-7 cells turned out to be
CXCR4 negative, while 7% of CAKI-1 cells (D relative MFI,
1.4) and 56% of A-498 cells (D relative MFI, 25.9) were CXCR4
positive, which was in well accordance with our RT–PCR results
(Figure 2).
Moreover, we used immunohistochemistry to conﬁrm differen-
tial CXCR4 expression on protein level in clear cell kidney
cancer. In contrast to the adjacent non-malignant kidney tissue,
we were able to demonstrate a heterogeneous but constantly detect-
able expression of CXCR4 antigen in malignant tissue (Figure 3).
CXCR4 is functional
To determine whether the detected CXCR4 protein was func-
tional, we analysed its ability to induce changes in
intracellular calcium levels after rhCXCL12a stimulation. Simul-
taneous confocal microscopy-analysis of several cells revealed a
heterogeneous reaction pattern of A-498 cells in response to
rhCXCL12a stimulation. While 2 mgm l
71 rhCXCL12a caused
a rapid and robust increase of intracellular calcium in a signiﬁ-
cant fraction of A-498 cells, others did not respond to the
stimulus. In contrast, treatment with 100 nmol bradykinin
induced a transient, large increase in calcium levels in all A-
498 cells (Figure 4).
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Figure 1 CXCR4 and CXCL12a mRNA expression using real-time RT–PCR. mRNA expression in four RCC cell lines (A-498, CAKI-1, CAKI-2 and HA-
7), tumour (T) and adjacent normal non-malignant tissue (N) of 10 patients with RCC is demonstrated as a ratio corrected for that of RPS9 mRNA ex-
pression. The median T/N ratio for all patients was 29.6 (range, 2.3–85.2) for CXCR4, and 0.36 (range: 0.1–2.3) for CXCL12a, respectively, displaying a
substantial upregulation of the receptor in malignant kidney tissue, while its ligand was less expressed compared to the corresponding normal renal tissue.
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In order to further analyse the molecular changes induced by
CXCL12a/CXCR4 signalling, differential expression of 1176 genes
in response to rhCXCL12a stimulation was investigated by cDNA
array analysis. Therefore, A-498 kidney cancer cells were incubated
either with or without rhCXCL12a for 6 h. Using background-
threshold values of 1.4 and a minimal expression ratio of 1.9
(stimulated vs unstimulated), 31 genes were found to be signiﬁ-
cantly inﬂuenced by rhCXCL12a, which could be grouped into
ﬁve major categories: genes involved in the CXCR4 signal trans-
duction pathway, transcription factors, regulators of translation
and the cell cycle, pro-apoptotic as well as miscellaneous genes
such as PAI-1, interleukins, cathepsin L precursor, neuregulin
and ECK (Table 2).
Moreover, we used a second array experiment to test the effects
of rhCXCL12a on A-498 kidney cancer cells after 18 h of stimula-
tion. Interestingly, CD82 was the only molecule that remained
upregulated (factor, +2.2), while the transcription factor, c-jun,
that was upregulated after 6 h were speciﬁcally downregulated after
18 h (factor, 71.9; data not shown).
DISCUSSION
RCC, especially when metastasised, continues to be a frustrating
tumour for clinicians to manage and treat. It is heterogeneous in
appearance, displaying diverse histological as well as functional
characteristics including cell proliferation, neoangiogenesis, necrosis
and modulation of immune responses. Though most RCC exhibit a
signiﬁcant inﬁltration of host immune cells, mainly of the mono-
nuclear lineage, the immune systems fails to establish adequate
anti-tumour activity, inevitably leading to tumour progression
and death.
Chemokines and their receptors are known to play an important
role in the process of leukocyte trafﬁcking and homing, especially
at sites of inﬂammation, infection, tissue injury, cell damage and
malignant tumour growth. Recent evidence suggests that these
proteins can also regulate non-leukocyte cell functions such as
angiogenesis/angiostasis, cell migration, activation of apoptotic cell
death, and proliferation (Wang et al, 1998). Thus, we have inves-
tigated the expression of CXC-chemokine receptors on primary
RCC cultures and on kidney cancer compared to normal kidney
tissue, detecting an alteration of the CXCL12/CXCR4 signalling
pathway in kidney cancer.
CXCR4 is one of the few chemokine receptors for which only
a single ligand has been identiﬁed so far, CXCL12. This chemo-
kine is constitutively expressed in bone marrow stromal cells as
well as various organs including brain, heart, lung, kidney,
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Figure 2 Flow-cytometric analysis of CXCR4 expression on A-498,
CAKI-1, CAKI-2 and HA-7 RCC cell lines. The cell lines CAKI-2 and HA-
7 did not express the receptor. In contrast, CAKI-1 showed weak and
A-498 strong positive staining for the CXCR4 mAb 12G5.
N
T
Figure 3 Immunohistochemical staining (biotin-streptavidin methodol-
ogy) of a clear cell renal carcinoma of well to moderate differentiation with
nearly diffuse cytoplasmatic expression of CXCR4 in malignant tissue (T) in
contrast to adjacent normal kidney tissue (N).
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Figure 4 Ca
2+ ﬂux in A-498 cells in response to rhCXCL12a. Using con-
focal microscopy, we detected a heterogeneous reaction pattern of A-498
cells in response to rhCXCL12a stimuli. While stimulation with 2 mgm l
71
rhCXCL12a caused a rapid and robust increase of intracellular calcium in a
fraction of A-498 cells (e.g. cell marked with an arrowhead), others did not
respond to the stimulus (e.g. cell marked with a star). In contrast, a large
increase in transient calcium was evoked by stimulation with 100 nmol bra-
dykinin in all A-498 cells. Upper part of Figure=microscopy of single cells;
lower part of Figure=intracellular Ca
2+ ﬂux visualised by fura-2 staining; ar-
row head, rhCXCL12a responding A-498cell; *-rhCXCL12a non respond-
ing A-498 cell.
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immune surveillance, B-cell progenitor proliferation, B-cell migra-
tion and chemotaxis of monocytes, resting T lymphocytes and
primitive haematopoietic cells (Nagasawa et al, 1994; Jo et al,
2000).
In the present study, which is the ﬁrst to evaluate CXCL12/
CXCR4 expression and its potential function in RCC, CXCL12a
expression was decreased in kidney cancer compared to normal
kidney tissue. None of the four tested RCC cell lines expressed
signiﬁcant amounts of CXCL12a mRNA. This may reﬂect their
cancerous nature basing on the observation that CXCL12a is not
expressed in premalignant colonic adenocarcinoma and reduced
in the majority of hepatoma and digestive tract carcinomas when
compared with adjacent non-cancerous tissue (Shibuta et al,
1997; Begum et al, 1999). It seems that CXCL12 counteracts carci-
nogenesis acting as a tumour-suppressor gene like molecule
(Shibuta et al, 1997; Jordan et al, 1999). This effect may also be
mediated by the ability of CXCL12a to inhibit the neovascularisa-
tion required for tumour growth. Thus, inhibition of CXCL12a
production by malignant cells may be advantageous for the growth
of certain tumours (Moore et al, 1998) – a concept that has not
been unopposed (Salcedo et al, 1999).
CXCR4 is constitutively expressed in a broad range of tissues,
including lymphatic tissues, thymus, brain, spleen, stomach, and
small intestine (Nagasawa et al, 1994). The functions of CXCR4
have not yet been fully understood, but it appears that it mediates
a large variety of functions including leukocyte development and
trafﬁcking, HIV-infection, correct foetal vascularisation and CNS
development and possibly cell division, tumourigenesis and growth
(Tachibana et al, 1998; Zou et al, 1998; Gabuzda and Wang, 1999).
Rempel et al (2000) observed a tumour grade-dependent surge of
CXCR4 mRNA levels in glioblastoma multiforme and that this
receptor is mainly expressed in regions of angiogenesis and degen-
erative, necrotic, and microcystic changes rather than in sections of
rapid cell proliferation. These data were conﬁrmed by others,
moreover expression of anti-sense CXCR4 transcripts in glioblasto-
ma cell lines caused neurite outgrowth and cellular differentiation;
treatment with CXCR4 speciﬁc antibodies lead to inhibition of cell
proliferation. Therefore, it was concluded that CXCR4 is required
for the proliferation of human glioblastoma tumours (Sehgal et
al, 1998a,b).
In a recent publication, CXCR4 was shown to be highly
expressed in breast cancer cells, malignant breast tumours as well
as metastases. CXCR4 signalling was associated with actin polymer-
isation, pseudopodia formation, and subsequently chemotactic and
invasive response. On the other hand CXCL12 exhibited peak levels
of expression in organs representing the ﬁrst destinations of breast
cancer metastasis, i.e. lymph nodes, lung, liver and bone marrow.
Neutralising the CXCL12-CXCR4 interaction signiﬁcantly impaired
metastasis to regional lymph nodes and lung in mice. Therefore, it
appears that the ﬁnal distribution of metastases in breast cancer
reﬂects the relative abundance of CXCL12 in the different organs
(Muller et al, 2001). As the pattern of metastasis between breast
and kidney cancer are comparable at least to some extent, similar
mechanism of CXCR4/CXCL12 in tumour spread might also be
active.
In the present study, we found an upregulated expression of
CXCR4 mRNA in kidney cancer samples compared to adjacent
normal tissue. Functional receptors were found on the cell surface
of A-498 RCC cells. These ﬁndings are in accordance with previous
reports dealing with epithelial and neuronal malignancies and indi-
cate that CXCR4 is overexpressed in rather dedifferentiated cells
and/or regions of angiogenesis, degeneration and necrosis. All those
cell forms can frequently be found in kidney cancer tissue.
However, as A-498 but not CAKI-1, CAKI-2 or HA-7 cancer cells
exhibited high CXCR4 mRNA expression levels, conditions like
dedifferentiation, proliferation and angiogenesis on one hand or
degeneration and necrosis on the other are certainly not solely
and exclusively responsible for the regulation of CXCR4 expression.
To further elucidate molecular changes induced by CXCR4-
mediated signalling, we employed cDNA expression arrays and
compared CXCL12a stimulated A-498 cells (for 6 and 18 h, respec-
tively) with unstimulated cells. After 6 h of stimulation, 31 genes
involved in various cellular processes were found to be speciﬁcally
up- or downregulated.
Concerning common signal transduction pathways also involved
in CXCR4 signalling, several molecules were upregulated. A most
interesting molecule in this group was CD82 (also termed kangai
1, suppressor of tumourigenicity 6, KAI1), as it was the only mole-
cule being upregulated after 6 h (factor, 2.3) and 18 h (factor, 2.2)
of CXCL12a stimulation, respectively. The transmembrane protein
CD82 is directly associated with the epidermal growth factor recep-
tor (EGFR) and other tyrosine kinase receptors and accelerates
desensitisation of tyrosine receptor induced signalling correlated
with an increased rate of receptor endocytosis (Odintsova et al,
2000). This attenuation of EGFR signalling by CD82 explains for
its recently identiﬁed role as metastasis suppressor gene for prostate
and pancreatic cancer (Dong et al, 1995; Guo et al, 1996). In addi-
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Table 2 Result of the cDNA expression array experiments. Comparison
of gene expression in natural/unstimulated and rhCXCL12a stimulated A-
498 RCC cells
Gene
(gene bank accession number) Unstimulated Stimulated
Signal transduction
paxillin (U14588) 91 193
c-src (K03218) 16 32
shb (X75342) 70 185
LAT (AF036905) 102 477
CD82/kangai-1/KAI1 (U20770) 11 25
CKI-g2 (U89896) 19 38
Gem (U10550) 21 44
Transcription factors
FBP2 (U69126) 27 86
EGR1 (M62829) 132 34
IRF-1 (X14454) 21 54
NF-kB p100 subunit (X61498) 56 188
I-kBa/MAD-3 (M69043) 11 42
c-Jun (J04111) 312 670
Fra-1 (X16707) 45 201
Translation
hnRNP I (X65372) 52 115
9G8 (L22053) 40 96
Cell cycle
cyclin D/bcl-1 (X59798) 15 32
cyclin G1 (U47413) 23 9
AHR (L19872) 38 218
RbAp48 (X74262) 105 281
Apoptosis
CRADD (U84388) 4 16
caspase-8/MCH5 (U60520) 28 54
caspase-10/MCH4 (U60519) 45 244
caspase-6/MCH2 (U20537) 13 55
NIK (Y10256) 19 40
Miscellaneous
PAI-1 (X04429) 10 44
IL-14 precursor (L15344) 14 46
IL-15 receptor a (U31628) 24 58
cathepsin L precursor (X12451) 40 170
neuregulin (L12261) 13 33
ECK (M59371) 19 41
For cDNA array analysis each spot was deﬁned by positioning of a grid of circles over
the array image; spot density for each gene was measured using Array-Vision soft-
ware (Version 5.1, Imaging Research, Canada). Local backgrounds were computed
for each spot; net density shown was determined by subtraction of this background
from the average density for each spot.
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of mononuclear cells (Lebel-Binay et al, 1995). Other speciﬁcally
regulated signal transduction molecules are given in Table 2.
The early growth response gene EGR1 was the only transcription
factor being constantly downregulated by rhCXCL12a (6 h factor,
73.9; 18 h factor, 72.1). EGR1 was shown to be overexpressed
in prostate cancer and to be involved in the regulation of different
steps involved in the initiation and progression of prostate cancer,
including mitogenesis, invasiveness, angiogenesis, and metastasis
(Svaren et al, 2000).
Two members of the AP-1 transcription factor family, i.e. Fra-1
(factor, +4.5) and c-Jun (factor, +2.1), were signiﬁcantly upregu-
lated after 6 h. After 18 h of rhCXCL12a stimulation, c-Jun
levels were signiﬁcantly downregulated (factor, 71.9; data not
shown). These altered c-Jun – Fra-1 ratios are interesting as
Fra-1 protein heterodimerises with different Jun proteins to form
stable AP-1 complexes with low transactivation potential. Thus,
Fra-1 represses AP-1 activity, which is known to be an important
mediator of tumour promoter action (Yoshioka et al, 1995).
Several other transcription factors, i.e. fuse binding protein
(FBP)-2, NF-kB p100 subunit and its feedback inhibitor I-kBa as
well as interferon regulatory factor (IRF)-1, showed only a transient
upregulation after 6 h but not 18 h of treatment. IRF-1 functions
as a regulator of the interferon system and key transcription factor
in the regulation of cell cycle and apoptosis. It has been demon-
strated to have antiproliferative and tumour suppressive
functions, particularly through its transcriptional activation of
IFN-a and IFN-b (Vaughan et al, 1997; Um et al, 2000).
rhCXCL12a also has an interesting but transient (i.e. 6 h) effect
on cell cycle regulatory molecules. The G1-phase cyclin-D as well as
the blockers of E2F-mediated transcription of S phase genes, the
aryl hydrocarbon receptor (AHR) as well as the retinoblastoma-
binding protein p48 (RbAp48), were signiﬁcantly upregulated.
On the other hand, cylcin-G1 levels were lower in rhCXCL12a trea-
ted cells. Cyclin-G1 expression has been shown to be tightly
regulated throughout the cell cycle in normal cells, peaking at
the S and G2/M phases of the cell cycle with lower levels in G1
(Reimer et al, 1999). Thus, CXCR4 signalling seems to have a
temporary cell cycle inhibiting effect on A-498 cells preventing
transition from G1 to S phase.
This cell cycle arresting effect is accompanied by an again tran-
sient upregulation of different pro-apoptotic molecules, i.e.
procaspases-8, -10 and -6, caspase and RIP adapter with death
domain (CRADD). While the ﬁrst two caspases are initiator
caspases, activated through death receptors like Fas or TNFR-1
and other stimuli, caspase-6 is an executioner caspase activated
by the apoptotic cascade. This increased expression of pro-apopto-
tic molecules is paralleled by the neutralisation of the anti-
apoptotic signalling through TNFR induced NF-kB by upregulated
I-kBa (Mustapha et al, 2000).
In summary, it appears that in the case of CXCR4 expressing
RCC, the CXCL12-CXCR4 pathway might be an interesting thera-
peutic target. The temporary and synchronous upregulation of a
metastasis inhibiting proteins (e.g. CD82), of proapoptotic mole-
cules (e.g. procaspases-8, -10 and -6, CRADD, I-kBa) and of
negative cell cycle regulators (e.g. cyclin-D, AHR, IRF-1, RbAp48)
is paralleled by a downregulation of molecules involved in cell cycle
progression and metastasis (e.g. EGR1, cyclin-G1). Therefore,
CXCL12 seems to be a promising molecule useful for the presensi-
bilisation of tumour cells in a combination-therapy of RCC.
However, further investigations are needed to determine a potential
biological and clinical impact on metastasis and tumour progres-
sion.
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